Evidence map›Paper›PMID 33626495›Full record

ArticleStem cell research2021

Knockout of the CEP290 gene in human induced pluripotent stem cells.

Joseph Fogerty, Brian D Perkins

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joseph FogertyDepartment of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: fogertj@ccf.org.
Brian D PerkinsDepartment of Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA.

Funding

RESOURCE/SERVICE CORE C - MOLECULAR INFORMATICS MODULEP30EY025585 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI Brian D Perkins · 2016 to 2026
$7.7M
Cilia Assembly and Transport in the Vertebrate RetinaR01EY017037 · NEI · TEXAS A&M UNIVERSITY · PI PERKINS, BRIAN D · 2006 to 2021
$5.5M
Stimulating Retina Regeneration from Muller Cells in Progressive Retinal DegenerationsR01EY030574 · NEI · CLEVELAND CLINIC LERNER COM-CWRU · PI PERKINS, BRIAN D · 2020 to 2022
$1.6M
NEI NIH HHS P30 EY025585NEI NIH HHS R01 EY017037NEI NIH HHS R01 EY030574
6 · The paper itself

Abstract

CEP290 is a principal component of the primary cilium and is important for the proper function of ciliated cells. CEP290 mutations have been linked to numerous ciliopathies, with a wide range of phenotypic severities, but with poor genotype:phenotype correlation. Here we have used CRISPR/Cas9 technology to target the CEP290 gene and generate a line of induced pluripotent stem cells that lack detectable CEP290 expression, but retain a normal karyotype and differentiation potential. This line of cells will be useful for the study of disorders resulting from CEP290 mutations.

Indexed as

Induced Pluripotent Stem CellsAntigens, NeoplasmCell Cycle ProteinsCRISPR-Cas SystemsCytoskeletal ProteinsHumansNeoplasm ProteinsAntigens, NeoplasmCell Cycle ProteinsCep290 protein, humanCytoskeletal ProteinsNeoplasm Proteins

Identifiers

PMID33626495
PMCPMC8127132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.